|
1
|
Boumahdi S, Driessens G, Lapouge G, Rorive
S, Nassar D, Le Mercier M, Delatte B, Caauwe A, Lenglez S, Nkusi E,
et al: SOX2 controls tumour initiation and cancer stem-cell
functions in squamous-cell carcinoma. Nature. 511:246–250. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chothia C and Jones EY: The molecular
structure of cell adhesion molecules. Annu Rev Biochem. 66:823–862.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reymond N, Fabre S, Lecocq E, Adelaïde J,
Dubreuil P and Lopez M: Nectin4/PRR4, a new Afadin-associated
member of the nectin family that trans-interacts with nectin1/PRR1
through V domain interaction. J Biol Chem. 276:43205–43215. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fabre S, Reymond N, Cocchi F, Menotti L,
Dubreuil P, Campadelli-Fiume G and Lopez M: Prominent role of the
Ig-like V domain in trans-interactions of nectins. Nectin3 and
nectin 4 bind to the predicted C′-C′-D beta-strands of the nectin1
V domain. J Biol Chem. 277:27006–27013. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yasumi M, Shimizu K, Honda T, Takeuchi M
and Takai Y: Role of each immunoglobulin-like loop of nectin for
its cell-cell adhesion activity. Biochem Biophys Res Commun.
302:61–66. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Takai Y, Miyoshi J, Ikeda W and Ogita H:
Nectins and nectin-like molecules: Roles in contact inhibition of
cell movement and proliferation. Nat Rev Mol Cell Biol. 9:603–615.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sakisaka T, Ikeda W, Ogita H, Fujita N and
Takai Y: The roles of nectins in cell adhesions: Cooperation with
other cell adhesion molecules and growth factor receptors. Curr
Opin Cell Biol. 19:593–602. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nakanishi H and Takai Y: Roles of nectins
in cell adhesion, migration and polarization. Biol Chem.
385:885–892. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pavlova NN, Pallasch C, Elia AE, Braun CJ,
Westbrook TF, Hemann M and Elledge SJ: A role for PVRL4-driven
cell-cell interactions in tumorigenesis. Elife. 2:e003582013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Takano A, Ishikawa N, Nishino R, Masuda K,
Yasui W, Inai K, Nishimura H, Ito H, Nakayama H, Miyagi Y, et al:
Identification of Nectin-4 oncoprotein as a diagnostic and
therapeutic target for lung cancer. Cancer Res. 69:6694–6703. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Derycke MS, Pambuccian SE, Gilks CB,
Kalloger SE, Ghidouche A, Lopez M, Bliss RL, Geller MA, Argenta PA,
Harrington KM and Skubitz AP: Nectin 4 overexpression in ovarian
cancer tissues and serum: Potential role as a serum biomarker. Am J
Clin Pathol. 134:835–845. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin X, Hu H, Pan Y and Gao S: The
prognostic role of expression of Nectin-4 in esophageal cancer. Med
Sci Monit. 25:10089–10094. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fabre-Lafay S, Monville F, Garrido-Urbani
S, Berruyer-Pouyet C, Ginestier C, Reymond N, Finetti P, Sauvan R,
Adélaïde J, Geneix J, et al: Nectin-4 is a new histological and
serological tumor associated marker for breast cancer. BMC Cancer.
7:732007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nishiwada S, Sho M, Yasuda S, Shimada K,
Yamato I, Akahori T, Kinoshita S, Nagai M, Konishi N and Nakajima
Y: Nectin-4 expression contributes to tumor proliferation,
angiogenesis and patient prognosis in human pancreatic cancer. J
Exp Clin Cancer Res. 34:302015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sakisaka T and Takai Y: Biology and
pathology of nectins and nectin-like molecules. Curr Opin Cell
Biol. 16:513–521. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yamada A, Fujita N, Sato T, Okamoto R,
Ooshio T, Hirota T, Morimoto K, Irie K and Takai Y: Requirement of
nectin, but not cadherin, for formation of claudin-based tight
junctions in annexin II-knockdown MDCK cells. Oncogene.
25:5085–5102. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lopez M, Aoubala M, Jordier F, Isnardon D,
Gomez S and Dubreuil P: The human poliovirus receptor related 2
protein is a new hematopoietic/endothelial homophilic adhesion
molecule. Blood. 92:4602–4611. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Reymond N, Borg JP, Lecocq E, Adelaide J,
Campadelli-Fiume G, Dubreuil P and Lopez M: Human nectin3/PRR3: A
novel member of the PVR/PRR/nectin family that interacts with
Afadin. Gene. 255:347–355. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Takai Y and Nakanishi H: Nectin and
Afadin: Novel organizers of intercellular junctions. J Cell Sci.
116:17–27. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Takai Y, Irie K, Shimizu K, Sakisaka T and
Ikeda W: Nectins and nectin-like molecules: Roles in cell adhesion,
migration, and polarization. Cancer Sci. 94:655–667. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Noyce RS, Bondre DG, Ha MN, Lin LT, Sisson
G, Tsao MS and Richardson CD: Tumor cell marker PVRL4 (nectin 4) is
an epithelial cell receptor for measles virus. PLoS Pathog.
7:e10022402011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bojesen KB, Clausen O, Rohde K,
Christensen C, Zhang L, Li S, Køhler L, Nielbo S, Nielsen J,
Gjørlund MD, et al: Nectin-1 binds and signals through the
fibroblast growth factor receptor. J Biol Chem. 287:37420–37433.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kanzaki N, Ogita H, Komura H, Ozaki M,
Sakamoto Y, Majima T, Ijuin T, Takenawa T and Takai Y: Involvement
of the nectin-Afadin complex in PDGF-induced cell survival. J Cell
Sci. 121:2008–2017. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ogita H and Takai Y: Cross-talk among
integrin, cadherin, and growth factor receptor: Roles of nectin and
nectin-like molecule. Int Rev Cytol. 265:1–54. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Martinez-Rico C, Pincet F, Perez E, Thiery
JP, Shimizu K, Takai Y and Dufour S: Separation force measurements
reveal different types of modulation of E-cadherin-based adhesion
by nectin-1 and −3. J Biol Chem. 280:4753–4760. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen L, Xie X, Zhang X, Jia W, Jian J,
Song C and Jin B: The expression, regulation and adhesion function
of a novel CD molecule, CD226, on human endothelial cells. Life
Sci. 73:2373–2382. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shibuya K, Shirakawa J, Kameyama T, Honda
S, Tahara-Hanaoka S, Miyamoto A, Onodera M, Sumida T, Nakauchi H,
Miyoshi H and Shibuya A: CD226 (DNAM-1) is involved in lymphocyte
function-associated antigen 1 costimulatory signal for naive T cell
differentiation and proliferation. J Exp Med. 198:1829–1839. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stanietsky N, Simic H, Arapovic J, Toporik
A, Levy O, Novik A, Levine Z, Beiman M, Dassa L, Achdout H, et al:
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell
cytotoxicity. Proc Natl Acad Sci USA. 106:17858–17863. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yu X, Harden K, Gonzalez LC, Francesco M,
Chiang E, Irving B, Tom I, Ivelja S, Refino CJ, Clark H, et al: The
surface protein TIGIT suppresses T cell activation by promoting the
generation of mature immunoregulatory dendritic cells. Nat Immunol.
10:48–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stanietsky N, Rovis TL, Glasner A, Seidel
E, Tsukerman P, Yamin R, Enk J, Jonjic S and Mandelboim O: Mouse
TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR. Eur
J Immunol. 43:2138–2150. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li M, Xia P, Du Y, Liu S, Huang G, Chen J,
Zhang H, Hou N, Cheng X, Zhou L, et al: T-cell immunoglobulin and
ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand
engagement suppresses interferon-γ production of natural killer
cells via β-arrestin 2-mediated negative signaling. J Biol Chem.
289:17647–17657. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu S, Zhang H, Li M, Hu D, Li C, Ge B,
Jin B and Fan Z: Recruitment of Grb2 and SHIP1 by the ITT-like
motif of TIGIT suppresses granule polarization and cytotoxicity of
NK cells. Cell Death Differ. 20:456–464. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Johnston RJ, Comps-Agrar L, Hackney J, Yu
X, Huseni M, Yang Y, Park S, Javinal V, Chiu H, Irving B, et al:
The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T
cell effector function. Cancer Cell. 26:923–937. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Takahashi K, Nakanishi H, Miyahara M,
Mandai K, Satoh K, Satoh A, Nishioka H, Aoki J, Nomoto A, Mizoguchi
A and Takai Y: Nectin/PRR: An immunoglobulin-like cell adhesion
molecule recruited to cadherin-based adherens junctions through
interaction with Afadin, a PDZ domain-containing protein. J Cell
Biol. 145:539–549. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Samanta D and Almo SC: Nectin family of
cell-adhesion molecules: Structural and molecular aspects of
function and specificity. Cell Mol Life Sci. 72:645–658. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shankar J and Nabi IR: Correction: Actin
cytoskeleton regulation of epithelial mesenchymal transition in
metastatic cancer cells. PLoS One. 10:e01327592015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Irie K, Shimizu K, Sakisaka T, Ikeda W and
Takai Y: Roles and modes of action of nectins in cell-cell
adhesion. Semin Cell Dev Biol. 15:643–656. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shimizu K and Takai Y: Roles of the
intercellular adhesion molecule nectin in intracellular signaling.
J Biochem. 134:631–636. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ikeda W, Nakanishi H, Miyoshi J, Mandai K,
Ishizaki H, Tanaka M, Togawa A, Takahashi K, Nishioka H, Yoshida H,
et al: Afadin: A key molecule essential for structural organization
of cell-cell junctions of polarized epithelia during embryogenesis.
J Cell Biol. 146:1117–1132. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Letessier A, Garrido-Urbani S, Ginestier
C, Fournier G, Esterni B, Monville F, Adélaïde J, Geneix J, Xerri
L, Dubreuil P, et al: Correlated break at PARK2/FRA6E and loss of
AF-6/Afadin protein expression are associated with poor outcome in
breast cancer. Oncogene. 26:298–307. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fukuyama T, Ogita H, Kawakatsu T, Fukuhara
T, Yamada T, Sato T, Shimizu K, Nakamura T, Matsuda M and Takai Y:
Involvement of the c-Src-Crk-C3G-Rap1 signaling in the
nectin-induced activation of Cdc42 and formation of adherens
junctions. J Biol Chem. 280:815–825. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kawakatsu T, Ogita H, Fukuhara T, Fukuyama
T, Minami Y, Shimizu K and Takai Y: Vav2 as a Rac-GDP/GTP exchange
factor responsible for the nectin-induced, c-Src- and
Cdc42-mediated activation of Rac. J Biol Chem. 280:4940–4947. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Takai Y, Ikeda W, Ogita H and Rikitake Y:
The immunoglobulin-like cell adhesion molecule nectin and its
associated protein Afadin. Annu Rev Cell Dev Biol. 24:309–342.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Okabe N, Shimizu K, Ozaki-Kuroda K,
Nakanishi H, Morimoto K, Takeuchi M, Katsumaru H, Murakami F and
Takai Y: Contacts between the commissural axons and the floor plate
cells are mediated by nectins. Dev Biol. 273:244–256. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ahmad F, Nasir A, Thiele H, Umair M, Borck
G and Ahmad W: A novel homozygous missense variant in NECTIN4
(PVRL4) causing ectodermal dysplasia cutaneous syndactyly syndrome.
Ann Hum Genet. 82:232–238. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Brancati F, Fortugno P, Bottillo I, Lopez
M, Josselin E, Boudghene-Stambouli O, Agolini E, Bernardini L,
Bellacchio E, Iannicelli M, et al: Mutations in PVRL4, encoding
cell adhesion molecule Nectin-4, cause ectodermal
dysplasia-syndactyly syndrome. Am J Hum Genet. 87:265–473. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Challita-Eid PM, Satpayev D, Yang P, An Z,
Morrison K, Shostak Y, Raitano A, Nadell R, Liu W, Lortie DR, et
al: Enfortumab vedotin antibody-drug conjugate targeting Nectin-4
is a highly potent therapeutic agent in multiple preclinical cancer
models. Cancer Res. 76:3003–3013. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhang Y, Liu S, Wang L, Wu Y, Hao J, Wang
Z, Lu W, Wang XA, Zhang F, Cao Y, et al: A novel PI3K/AKT signaling
axis mediates Nectin-4-induced gallbladder cancer cell
proliferation, metastasis and tumor growth. Cancer Lett.
375:179–189. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang Y, Zhang J, Shen Q, Yin W, Huang H,
Liu Y and Ni Q: High expression of Nectin-4 is associated with
unfavorable prognosis in gastric cancer. Oncol Lett. 15:8789–8795.
2018.PubMed/NCBI
|
|
50
|
Zhang Y, Chen P, Yin W, Ji Y, Shen Q and
Ni Q: Nectin-4 promotes gastric cancer progression via the PI3K/AKT
signaling pathway. Hum Pathol. 72:107–116. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Das D, Satapathy SR, Siddharth S, Nayak A
and Kundu CN: Nectin-4 increased the 5-FU resistance in colon
cancer cells by inducing the PI3K-AKT cascade. Cancer Chemother
Pharmacol. 76:471–479. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang J, Liu K, Peng P, Li S, Ye Z, Su Y,
Liu S, Qin M and Huang J: Upregulation of Nectin-4 is associated
with ITGB1 and vasculogenic mimicry and may serve as a predictor of
poor prognosis in colorectal cancer. Oncol Lett. 18:1163–1170.
2019.PubMed/NCBI
|
|
53
|
Siddharth S, Nayak A, Das S, Nayak D,
Panda J, Wyatt MD and Kundu CN: The soluble Nectin-4 ecto-domain
promotes breast cancer induced angiogenesis via endothelial
Integrin-β4. Int J Biochem Cell Biol. 102:151–160. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Siddharth S, Goutam K, Das S, Nayak A,
Nayak D, Sethy C, Wyatt MD and Kundu CN: Nectin-4 is a breast
cancer stem cell marker that induces WNT/β-catenin signaling via
Pi3k/Akt axis. Int J Biochem Cell Biol. 89:85–94. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Deng H, Shi H, Chen L, Zhou Y and Jiang J:
Over-expression of Nectin-4 promotes progression of esophageal
cancer and correlates with poor prognosis of the patients. Cancer
Cell Int. 19:1062019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Folkman J: Angiogenesis in cancer,
vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Carmeliet P and Jain RK: Angiogenesis in
cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Yu X, Zhen Y, Yang H, Wang H, Zhou Y, Wang
E, Marincola FM, Mai C, Chen Y, Wei H, et al: Loss of connective
tissue growth factor as an unfavorable prognosis factor activates
miR-18b by PI3K/AKT/C-Jun and C-Myc and promotes cell growth in
nasopharyngeal carcinoma. Cell Death Dis. 4:e6342013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Bousquet E, Calvayrac O, Mazières J,
Lajoie-Mazenc I, Boubekeur N, Favre G and Pradines A: RhoB loss
induces Rac1-dependent mesenchymal cell invasion in lung cells
through PP2A inhibition. Oncogene. 35:1760–1769. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Karlsson R, Pedersen ED, Wang Z and
Brakebusch C: Rho GTPase function in tumorigenesis. Biochim Biophys
Acta. 1796:91–98. 2009.PubMed/NCBI
|
|
61
|
Schmidt A and Hall A: Guanine nucleotide
exchange factors for Rho GTPases: Turning on the switch. Genes Dev.
16:1587–1609. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Guo Y, Kenney SR, Muller CY, Adams S,
Rutledge T, Romero E, Murray-Krezan C, Prekeris R, Sklar LA, Hudson
LG, et al: R-ketorolac targets Cdc42 and Rac1 GTPases and alters
ovarian tumor cell behaviors critical for invasion and metastasis.
Cancer Res. 75 (Suppl 15):S40442015.
|
|
63
|
Vial E, Sahai E and Marshall CJ: ERK-MAPK
signaling coordinately regulates activity of Rac1 and RhoA for
tumor cell motility. Cancer Cell. 4:67–79. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Coso OA, Chiariello M, Yu JC, Teramoto H,
Crespo P, Xu N, Miki T and Gutkind JS: The small GTP-binding
proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK
signaling pathway. Cell. 81:1137–1146. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Eswaran J, Li DQ, Shah A and Kumar R:
Molecular pathways: Targeting p21-activated kinase 1 signaling in
cancer-opportunities, challenges, and limitations. Clin Cancer Res.
18:3743–3749. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Henderson V, Smith B, Burton LJ, Randle D,
Morris M and Odero-Marah VA: Snail promotes cell migration through
PI3K/AKT-dependent Rac1 activation as well as PI3K/AKT-independent
pathways during prostate cancer progression. Cell Adh Migr.
9:255–264. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Ray RM, Vaidya RJ and Johnson LR: MEK/ERK
regulates adherens junctions and migration through Rac1. Cell Motil
Cytoskeleton. 64:143–156. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Slabáková E, Pernicová Z, Slavíčková E,
Staršíchová A, Kozubík A and Souček K: TGF-β1-induced EMT of
non-transformed prostate hyperplasia cells is characterized by
early induction of SNAI2/Slug. Prostate. 71:1332–1343. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Hao RT, Zheng C, Wu CY, Xia EJ, Zhou XF,
Quan RD and Zhang XH: NECTIN4 promotes papillary thyroid cancer
cell proliferation, migration, and invasion and triggers EMT by
activating AKT. Cancer Manag Res. 11:2565–2578. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Carey LA, Perou CM, Livasy CA, Dressler
LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S,
et al: Race, breast cancer subtypes, and survival in the carolina
breast cancer study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Athanassiadou AM, Patsouris E, Tsipis A,
Gonidi M and Athanassiadou P: The significance of survivin and
Nectin-4 expression in the prognosis of breast carcinoma. Folia
Histochem Cytobiol. 49:26–33. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Rajc J, Gugić D, Fröhlich I, Marjanović K
and Dumenčić B: Prognostic role of Nectin-4 expression in luminal B
(HER2 negative) breast cancer. Pathol Res Pract. 213:1102–1108.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
M-Rabet M, Cabaud O, Josselin E, Finetti
P, Castellano R, Farina A, Agavnian-Couquiaud E, Saviane G,
Collette Y, Viens P, et al: Nectin-4: A new prognostic biomarker
for efficient therapeutic targeting of primary and metastatic
triple-negative breast cancer. Ann Oncol. 28:769–776. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Zeindler J, Soysal SD, Piscuoglio S, Ng
CKY, Mechera R, Isaak A, Weber WP, Muenst S and Kurzeder C:
Nectin-4 expression is an independent prognostic biomarker and
associated with better survival in triple-negative breast cancer.
Front Med (Lausanne). 6:2002019. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Lattanzio R, Ghasemi R, Brancati F, Sorda
RL, Tinari N, Perracchio L, Iacobelli S, Mottolese M, Natali PG and
Piantelli M: Membranous Nectin-4 expression is a risk factor for
distant relapse of T1-T2, N0 luminal-A early breast cancer.
Oncogenesis. 3:e1182014. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Fabre-Lafay S, Garrido-Urbani S, Reymond
N, Goncalves A, Dubreuil P and Lopez M: Nectin-4, a new serological
breast cancer marker, is a substrate for tumor necrosis
factor-alpha-converting enzyme (TACE)/ADAM-17. J Biol Chem.
280:19543–19550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Hibbs K, Skubitz KM, Pambuccian SE, Casey
RC, Burleson KM, Oegema TR Jr, Thiele JJ, Grindle SM, Bliss RL and
Skubitz AP: Differential gene expression in ovarian carcinoma:
Identification of potential biomarkers. Am J Pathol. 165:397–414.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Nabih ES, Abdel Motaleb FI and Salama FA:
The diagnostic efficacy of nectin 4 expression in ovarian cancer
patients. Biomarkers. 19:498–504. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Boylan KL, Buchanan PC, Manion RD, Shukla
DM, Braumberger K, Bruggemeyer C and Skubitz AP: The expression of
Nectin-4 on the surface of ovarian cancer cells alters their
ability to adhere, migrate, aggregate, and proliferate. Oncotarget.
8:9717–9738. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Pradeep S, Kim SW, Wu SY, Nishimura M,
Chaluvally Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ,
Bischoff FZ, et al: Hematogenous metastasis of ovarian cancer:
Rethinking mode of spread. Cancer Cell. 26:77–91. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Desoize B and Jardillier J: Multicellular
resistance: A paradigm for clinical resistance? Crit Rev Oncol
Hematol. 36:193–207. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Boylan KLM, Manion RD, Shah H, Skubitz KM
and Skubitz APN: Inhibition of ovarian cancer cell spheroid
formation by synthetic peptides derived from Nectin-4. Int J Mol
Sci. 21:46372020. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Erturk K, Karaman S, Dagoglu N, Serilmez
M, Duranyildiz D and Tas F: Serum Nectin-2 and Nectin-4 are
diagnostic in lung cancer: Which is superior? Wien Klin Wochenschr.
131:419–426. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Alhalabi O, Rafei H, Shah A,
Siefker-Radtke A, Campbell M and Gao J: Targeting advanced
urothelial carcinoma-developing strategies. Curr Opin Oncol.
31:207–215. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Tomiyama E, Fujita K, Rodriguez Pena MDC,
Taheri D, Banno E, Kato T, Hatano K, Kawashima A, Ujike T, Uemura
M, et al: Expression of Nectin-4 and PD-L1 in upper tract
urothelial carcinoma. Int J Mol Sci. 21:53902020. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Izumi H, Hirabayashi K, Nakamura N and
Nakagohri T: Nectin expression in pancreatic adenocarcinoma:
Nectin-3 is associated with a poor prognosis. Surg Today.
45:487–494. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Ma J, Sheng Z, Lv Y, Liu W, Yao Q, Pan T,
Xu Z, Zhang C and Xu G: Expression and clinical significance of
Nectin-4 in hepatocellular carcinoma. Onco Targets Ther. 9:183–190.
2016.PubMed/NCBI
|
|
88
|
Thomas A, Teicher BA and Hassan R:
Antibody-drug conjugates for cancer therapy. Lancet Oncol.
17:e254–e262. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Sarfaty M and Rosenberg JE: Antibody-drug
conjugates in urothelial carcinomas. Curr Oncol Rep. 22:132020.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Leyton JV: Improving receptor-mediated
intracellular access and accumulation of antibody therapeutics-the
tale of HER2. Antibodies (Basel). 9:322020. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Rosenberg JE, O'Donnell PH, Balar AV,
McGregor BA, Heath EI, Yu EY, Galsky MD, Hahn NM, Gartner EM,
Pinelli JM, et al: Pivotal trial of enfortumab vedotin in
urothelial carcinoma after platinum and anti-programmed death
1/programmed death ligand 1 therapy. J Clin Oncol. 37:2592–2600.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Bednova O and Leyton JV: Targeted
molecular therapeutics for bladder cancer-a new option beyond the
mixed fortunes of immune checkpoint inhibitors? Int J Mol Sci.
21:72682020. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
No authors listed. Targeting Nectin-4 in
bladder cancer. Cancer Discov. 7:OF32017. View Article : Google Scholar
|
|
94
|
Rosenberg J, Sridhar SS, Zhang J, Smith D,
Ruether D, Flaig TW, Baranda J, Lang J, Plimack ER, Sangha R, et
al: EV-101: A phase I study of single-agent enfortumab vedotin in
patients with Nectin-4-positive solid tumors, including metastatic
urothelial carcinoma. J Clin Oncol. 38:1041–1049. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Yu EY, Petrylak DP, O'Donnell PH, Lee JL,
van der Heijden MS, Loriot Y, Stein MN, Necchi A, Kojima T,
Harrison MR, et al: Enfortumab vedotin after PD-1 or PD-L1
inhibitors in cisplatin-ineligible patients with advanced
urothelial carcinoma (EV-201): A multicentre, single-arm, phase 2
trial. Lancet Oncol. 22:872–882. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Hoimes CJ, Rosenberg JE, Petrylak DP,
Carret AS, Sasse C, Chaney MF and Flaig TW: Study EV-103: New
cohorts testing enfortumab vedotin alone or in combination with
pembrolizumab in muscle invasive urothelial cancer. J Clin Oncol.
38 (Suppl 6):TPS5952020. View Article : Google Scholar
|
|
97
|
Powles T, Rosenberg JE, Sonpavde GP,
Loriot Y, Durán I, Lee JL, Matsubara N, Vulsteke C, Castellano D,
Wu C, et al: Enfortumab vedotin in previously treated advanced
urothelial carcinoma. N Engl J Med. 384:1125–1135. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Delpeut S, Sisson G, Black KM and
Richardson CD: Measles virus enters breast and colon cancer cell
lines through a PVRL4-mediated macropinocytosis pathway. J Virol.
91:e02191–16. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Griffin DE and Oldstone MB: Measles:
History and basic biology. Introduction. Curr Top Microbiol
Immunol. 329:12009.PubMed/NCBI
|
|
100
|
Bluming AZ and Ziegler JL: Regression of
Burkitt's lymphoma in association with measles infection. Lancet.
2:105–106. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Taqi AM, Abdurrahman MB, Yakubu AM and
Fleming AF: Regression of Hodgkin's disease after measles. Lancet.
1:11121981. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Li H, Peng KW and Russell SJ: Oncolytic
measles virus encoding thyroidal sodium iodide symporter for
squamous cell cancer of the head and neck radiovirotherapy. Hum
Gene Ther. 23:295–301. 2012. View Article : Google Scholar : PubMed/NCBI
|
